CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) - USD ($) $ in Thousands	Total	Follow-on Public Offering	Common Stock	Common Stock Follow-on Public Offering	Additional Paid-In Capital	Additional Paid-In Capital Follow-on Public Offering	Accumulated Other Comprehensive Income/(Loss)	Accumulated Deficit
Beginning balance at Dec. 31, 2022	$ 685,188		$ 9		$ 1,388,300		$ (1,780)	$ (701,341)
Beginning balance, shares at Dec. 31, 2022			90,411,912
Issuance of common stock pursuant to stock option exercises	499				499
Issuance of common stock pursuant to stock option exercises, shares			118,747
Issuance of common stock related to vesting of restricted stock units, shares			85,891
Issuance of common stock from follow-on offering, net of offering costs		$ 323,706		$ 2		$ 323,704
Issuance of common stock from follow-on offering, net of offering costs, shares				15,681,818
Repurchases of early exercised stock, shares			(291)
Stock-based compensation expense	9,699				9,699
Net unrealized gain (loss) on marketable securities	1,224						1,224
Net Income (Loss)	(68,098)							(68,098)
Ending balance at Mar. 31, 2023	952,218		$ 11		1,722,202		(556)	(769,439)
Ending balance, shares at Mar. 31, 2023			106,298,077
Beginning balance at Dec. 31, 2022	685,188		$ 9		1,388,300		(1,780)	(701,341)
Beginning balance, shares at Dec. 31, 2022			90,411,912
Ending balance at Dec. 31, 2023	1,826,194		$ 16		2,963,342		544	(1,137,708)
Ending balance, shares at Dec. 31, 2023			164,674,594
Issuance of common stock pursuant to stock option exercises	810				810
Issuance of common stock pursuant to stock option exercises, shares			73,342
Issuance of common stock related to vesting of restricted stock units, shares			165,078
Stock-based compensation expense	16,208				16,208
Net unrealized gain (loss) on marketable securities	(1,742)						(1,742)
Net Income (Loss)	(116,003)							(116,003)
Ending balance at Mar. 31, 2024	$ 1,725,467		$ 16		$ 2,980,360		$ (1,198)	$ (1,253,711)
Ending balance, shares at Mar. 31, 2024			164,913,014